

## References

S-224

1. Cornell R. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. *Biol Blood Marrow Transplant.* 2017; 23:60-66.
2. Leblond V. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood.* 2016; 128(10):1321-1328.
3. Abeykoon J. New developments in the management of Waldenström macroglobulinemia. *Cancer Manag Res.* 2017; 9:73-83.
4. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol.* 2017; 3(9):1257-1265
5. Talaulikar D, Tam CS, Joshua D, et al. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Intern Med J.* 2017; 47(1):35-49.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2022.
7. Oza A, Rajkumar SV. Waldenström macroglobulinemia: prognosis and management. *Blood Cancer J.* 2016; 6(2):e391.
8. Gertz MA. Waldenström macroglobulinemia: 2019 Update on diagnosis, risk stratification, and management. *Am J Hematol.* 2019; 94(2):266-276.
9. Parrondo RD, Reljic T, Iqbal M, et al. Efficacy of autologous and allogeneic hematopoietic cell transplantation in Waldenström macroglobulinemia: A systematic review and meta-analysis. *Clin Lymphoma Myeloma Leuk.* 2020;20(10):e694-e711.
10. Cornell RF, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. *Biol Blood Marrow Transplant.* 2017;23(1):60-66.